Aurobindo Pharma Limited has announced its consolidated financial results for the quarter and year ended March 31, 2026. The company reported a 5.6% YoY increase in revenue from operations to INR 8,853 Cr for the fourth quarter. Net profit for the quarter stood at INR 921 Cr. The full-year results reflect steady growth, with total revenue for FY26 reaching INR 33,653 Cr, marking a 6.1% YoY growth.
Financial Highlights
During the fourth quarter of the financial year 2026, Aurobindo Pharma achieved INR 8,853 Cr in revenue from operations, a 5.6% improvement compared to the same period in the previous year. The company’s EBITDA (before Forex, Other Income, and exceptional items) was reported at INR 1,801 Cr with an EBITDA margin of 20.3%. For the full FY26, the company recorded a total revenue of INR 33,653 Cr, reflecting a solid 6.1% growth over the previous year, while the annual net profit stood at INR 3,503 Cr.
Segment Performance
The company saw diverse performance across its business segments. Europe Formulations were a major highlight, with revenues increasing by 30.2% YoY to INR 2,795 Cr, hitting a milestone of over €1 billion in annual revenue. In contrast, US Formulations revenue was INR 3,543 Cr, accounting for 40.0% of the total consolidated revenue. Growth Markets also showed strong momentum, increasing by 24.7% YoY to INR 980 Cr, while API revenues grew by 12.9% YoY to INR 1,208 Cr.
Strategic Milestones and R&D
Aurobindo Pharma continues to invest heavily in its future, with R&D spending (including depreciation) totaling INR 400 Cr, representing 4.5% of revenues for the quarter. The company maintained a strong product pipeline, receiving final approval for 9 ANDAs from the USFDA during the quarter. By the end of FY26, the company had filed a cumulative 888 ANDAs. Furthermore, the firm successfully completed the acquisition of the Khandelwal laboratories (non-oncology) business for USD 317 million, strengthening its market position.
Source: BSE
